EGFR and non-small cell lung carcinoma: Furmonertinib received breakthrough therapy designation (BTD) for use in previously treated patients with EGFR exon 20 insertion-positive NSCLC after data from the phase 1b FAVOUR trial showed ORR 69% in treatment-naïve patients, with grade ≥ 3 AEs occurring in 13–29% of patients across cohorts (Table 1).